27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
These findings suggested high prevalence and detrimental impact of DSD in hospitalized older adults, highlighting a need for early identification, prevention, and treatments. 3 key findings →
Design: systematic review Participants: 81 Evidence: high
Full summary, score breakdown and related studies → Original source
We present a range of trigger tools spanning different hospital settings and patient populations. 1 key finding →
Design: systematic review Participants: 17,000 Evidence: high
Full summary, score breakdown and related studies → Original source
Fifty-two studies (20 randomised; 32 non-randomised) with 4786 participants diagnosed with cancer (n = 4491), dementia (n = 43), AIDS (n = 235), spasticity (n = 16), NORSE syndrome (n = 1) were included. 1 key finding →
Design: meta-analysis Participants: 4,491 Evidence: high
Full summary, score breakdown and related studies → Original source
Hypertension significantly increases the risk of vascular dementia. 4 key findings →
Design: meta-analysis Participants: 768 Evidence: high
Full summary, score breakdown and related studies → Original source
In this study, NPTs have excellent potential to improve cognition in people with dementia, and PBM may have more significant benefits in improving cognition than the other four NPTs. 5 key findings →
Design: systematic review Participants: 38 Evidence: high
Full summary, score breakdown and related studies → Original source
Based on this meta-analytic survey of the literature, increased amyloid burden has small but nontrivial associations with specific domains of cognitive performance in individuals who are currently cognitively normal. 3 key findings →
Design: meta-analysis Participants: 7,140 Evidence: high
Full summary, score breakdown and related studies → Original source
Brain networks or 'connectomes' include a minority of highly connected hub nodes that are functionally valuable, because their topological centrality supports integrative processing and adaptive behaviours. 5 key findings →
Design: meta-analysis Participants: 56 Evidence: high
Full summary, score breakdown and related studies → Original source
This analysis indicated that patients with type 2 diabetes under treatment with DPP-4 inhibitors presented with the lowest risk of dementia, followed by those treated with metformin and thiazolidinedione, while treatment with insulin was associated with the highest risk. 5 key findings →
Design: meta-analysis Participants: 530,355 Evidence: high
Full summary, score breakdown and related studies → Original source
Metformin, thiazolidinediones, pioglitazone, GLP1RAs and SGLT2is were associated with reduced risk of dementia. 5 key findings →
Design: meta-analysis Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
Three donepezil, two galantamine, one rivastigmine, and two memantine trials, comprising 3093 patients on the study drugs and 2090 patients on placebo, met the selection criteria. 2 key findings →
Design: systematic review Participants: 3,093 Evidence: high
Full summary, score breakdown and related studies → Original source
Study objectives Mounting evidence implicates disturbed sleep or lack of sleep as one of the risk factors for Alzheimer's disease (AD), but the extent of the risk is uncertain. 4 key findings →
Design: systematic review Participants: 69,216 Evidence: high
Full summary, score breakdown and related studies → Original source
Fewer than half of the older adults dispensed donepezil in Ontario would have been eligible to participate in the RCTs that established the efficacy of this drug. 4 key findings →
Design: systematic review Participants: 3,423 Evidence: high
Full summary, score breakdown and related studies → Original source
Both t-tau and p-tau are suitable AD blood biomarkers, and p-tau217 is more sensitive than other tau biomarkers to differentiate MCI and AD. 3 key findings →
Design: systematic review Participants: 56 Evidence: high
Full summary, score breakdown and related studies → Original source
This meta-analysis pooled 30 studies (nearly 9,800 people from 10 countries) to see how well p-tau217 measured in blood or spinal fluid detects Alzheimer's amyloid and tau pathology compared with PET scans. 4 key findings →
Design: meta-analysis Participants: 9,787 Evidence: high
Full summary, score breakdown and related studies → Original source
This was, at the time, the largest genetic study of Alzheimer's disease ever done, comparing DNA from over 111,000 people with the disease (or a strong family history) to nearly 680,000 people without it. 4 key findings →
Design: meta-analysis Participants: 788,989 Evidence: high
Full summary, score breakdown and related studies → Original source
One randomized clinical trial (RCT) (n = 4005) examined the direct effect of screening for cognitive impairment on patient outcomes, including potential harms, finding no significant differences in health-related quality of life at 12 months (effect size, 0.009 [95% CI, -0.063 to 0.080]). 2 key findings →
Design: meta-analysis Participants: 4,005 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A healthy lifestyle as a composite score is associated with a substantially lower risk of Alzheimer's dementia. 5 key findings →
Design: meta-analysis Participants: 1,845 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
With no effective treatments for cognitive decline or dementia, improving the evidence base for modifiable risk factors is a research priority. 1 key finding →
Design: meta-analysis Participants: 48,522 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Substantial variation in the prevalence of dementia in Parkinson's disease (PDD) has been reported. 2 key findings →
Design: systematic review Participants: 1,767 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 95 unique studies were included in this systematic review, of which 74 with 2 760 379 unique patients were also included in 5-year age band meta-analyses. 5 key findings →
Design: systematic review Participants: 95 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Decades of research have revealed numerous risk factors for mental disorders beyond genetics, but their consistency and magnitude remain uncer-tain. 1 key finding →
Design: meta-analysis Participants: 176 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Vascular cognitive impairment (VCI) describes a broad spectrum of cognitive impairments caused by cerebrovascular disease, ranging from mild cognitive impairment to dementia. 4 key findings →
Design: meta-analysis Participants: 2,193 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Using cross-population GWAS meta-analyses, we identify novel LOAD susceptibility loci in/near LRRC4C and LHX5-AS1, both with known roles in neuronal development, as well as several novel population-unique loci. 1 key finding →
Design: meta-analysis Participants: 409,589 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 17 articles were identified. Plasma Aβ42/40 ratio was inversely correlated with aPET positivity r = -0.48 (95% confidence interval (CI): -0.65--0.31). 5 key findings →
Design: systematic review Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source
Thinning of retinal layers, measured using optical coherence tomography (OCT), is associated with some neurodegenerative disorders such as established Alzheimer's disease and multiple sclerosis. 5 key findings →
Design: systematic review Participants: 622 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →